Random Checks Now Routine: China To Inspect Your Factories Near And Far
Executive Summary
An officially released new regulation in China legalizes overseas inspections of drug and device makers, making the risk-based inspections routine tasks that could also expand to manufacturers' R&D partners and third-party suppliers of ingredients, excipients or packaging materials.
You may also be interested in...
China In 2019: Coming Regulatory Changes To Keep On Your Radar
From heightened overseas manufacturing inspections to a new patent challenge mechanism, important regulatory changes are coming in China this year, and implementation could potentially derail your operations in this key market.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.